

Ate G J Van Der Zee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3786073/publications.pdf>

Version: 2024-02-01

41
papers

2,566
citations

186265

28
h-index

276875

41
g-index

43
all docs

43
docs citations

43
times ranked

3529
citing authors

#	ARTICLE	IF	CITATIONS
1	History and Updates of the GROINSS-V Studies. <i>Cancers</i> , 2022, 14, 1956.	3.7	8
2	Trial in progress: Phase II activity trial of high-dose radiation and chemosensitization in patients with macrometastatic lymph node spread after sentinel node biopsy in vulvar cancer: Groningen International Study on Sentinel Nodes in Vulvar Cancer III (GROINSS-V III/NRG-GY024).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5624-TPS5624.	1.6	0
3	First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers. <i>Molecular Therapy</i> , 2021, 29, 611-625.	8.2	48
4	<scp>DNA</scp> methylation markers as triage test for the early identification of cervical lesions in a Chinese population. <i>International Journal of Cancer</i> , 2021, 148, 1768-1777.	5.1	13
5	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. <i>Journal of Clinical Oncology</i> , 2021, 39, 3623-3632.	1.6	69
6	Radical vulvectomy with right gluteal and left medial thigh V-Y advancement flap reconstruction. <i>Journal of the Turkish German Gynecology Association</i> , 2021, 22, 339-342.	0.6	1
7	Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. <i>PLoS ONE</i> , 2020, 15, e0235766.	2.5	2
8	Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. <i>Cancer Letters</i> , 2019, 461, 102-111.	7.2	40
9	DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort. <i>International Journal of Cancer</i> , 2019, 144, 746-754.	5.1	37
10	Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3928-3940.	7.0	35
11	Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: A systematic review. <i>Gynecologic Oncology</i> , 2018, 148, 622-631.	1.4	83
12	ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. <i>Oncogene</i> , 2018, 37, 4611-4625.	5.9	72
13	Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1. <i>Cancer Letters</i> , 2018, 433, 242-251.	7.2	16
14	Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer. <i>Epigenetics</i> , 2018, 13, 769-778.	2.7	43
15	ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 176-184.	7.4	69
16	Proteomic alterations in early stage cervical cancer. <i>Oncotarget</i> , 2018, 9, 18128-18147.	1.8	20
17	European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 832-837.	2.5	149
18	Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. <i>BMC Medicine</i> , 2017, 15, 116.	5.5	44

#	ARTICLE	IF	CITATIONS
19	Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. PLoS ONE, 2016, 11, e0165385.	2.5	13
20	Repeat sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma is feasible. Gynecologic Oncology, 2016, 140, 415-419.	1.4	30
21	Breaking the DNA damage response to improve cervical cancer treatment. Cancer Treatment Reviews, 2016, 42, 30-40.	7.7	54
22	Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation. Molecular Therapy, 2016, 24, 536-547.	8.2	33
23	Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Drug Resistance Updates, 2016, 24, 55-69.	14.4	52
24	Genome-wide methylome analysis using MethylCap-seq uncovers 4 hypermethylated markers with high sensitivity for both adeno- and squamous-cell cervical carcinoma. Oncotarget, 2016, 7, 80735-80750.	1.8	15
25	Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival. Oncotarget, 2016, 7, 18573-18584.	1.8	40
26	Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods. Scientific Reports, 2015, 5, 14495.	3.3	41
27	Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer. PLoS ONE, 2015, 10, e0135012.	2.5	7
28	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Medicine, 2015, 7, 108.	8.2	138
29	Prolonged re-expression of the hypermethylated gene <i>EPB41L3</i> using artificial transcription factors and epigenetic drugs. Epigenetics, 2015, 10, 384-396.	2.7	28
30	Update on sentinel lymph node biopsy for early-stage vulvar cancer. Gynecologic Oncology, 2015, 138, 472-477.	1.4	34
31	Comparing the Cervista HPV HR Test and Hybrid Capture 2 Assay in a Dutch Screening Population: Improved Specificity of the Cervista HPV HR Test by Changing the Cut-Off. PLoS ONE, 2014, 9, e0101930.	2.5	11
32	Clinical Validation of the Cervista HPV HR Test According to the International Guidelines for Human Papillomavirus Test Requirements for Cervical Cancer Screening. Journal of Clinical Microbiology, 2014, 52, 4391-4393.	3.9	20
33	Functional validation of putative tumor suppressor gene <i>C13ORF18</i> in cervical cancer by Artificial Transcription Factors. Molecular Oncology, 2013, 7, 669-679.	4.6	39
34	<i>CADM1</i> and <i>MAL</i> promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. International Journal of Cancer, 2013, 133, 1293-1299.	5.1	100
35	Methylation Markers for <i>CCNA1</i> and <i>C13ORF18</i> Are Strongly Associated with High-Grade Cervical Intraepithelial Neoplasia and Cervical Cancer in Cervical Scrapings. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3000-3007.	2.5	62
36	Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer. Journal of Clinical Oncology, 2008, 26, 884-889.	1.6	684

#	ARTICLE	IF	CITATIONS
37	Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome. <i>Cancer Research</i> , 2008, 68, 2661-2670.	0.9	131
38	Assessment of gene promoter hypermethylation for detection of cervical neoplasia. <i>International Journal of Cancer</i> , 2006, 119, 1908-1914.	5.1	97
39	A Virosomal Immunization Strategy against Cervical Cancer and Pre-Malignant Cervical Disease. <i>Antiviral Therapy</i> , 2006, 11, 717-728.	1.0	20
40	OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. <i>Cancer</i> , 2001, 92, 2837-2844.	4.1	94
41	Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. <i>International Journal of Cancer</i> , 1994, 59, 607-611.	5.1	71